Effects of Concurrent Topotecan and Radiation on 6-Month Progression-Free Survival in the Primary Treatment of Glioblastoma Multiforme

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 1, 2009, Pages 164-169

  Grabenbauer, Gerhard G ^a   Gerber, Klaus Dieter ^a   Ganslandt, Oliver ^a   Richter, Andrea ^b   Klautke, Gunther ^c   Birkmann, Josef ^d   Meyer, Martin ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Cancer Registry of Erlangen Nürnberg   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d Medical Hospital Nürnberg   (Germany)

Author keywords

Brain tumor; Quality of life; Radiation; Topotecan

Indexed keywords

HEAT RADIATION; MAGNETIC RESONANCE IMAGING; RADIOTHERAPY; REGRESSION ANALYSIS;

BRAIN TUMORS; EASTERN COOPERATIVE ONCOLOGY GROUP; GLIOBLASTOMA MULTIFORME; PROGRESSION FREE SURVIVAL; PROGRESSION FREE SURVIVAL RATES; QUALITY OF LIFE; RECURSIVE PARTITIONING ANALYSIS; TOPOTECAN;

RADIATION EFFECTS;

TOPOTECAN;

ADULT; ANEMIA; ARTICLE; BOLUS INJECTION; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 68649103010     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.04.015     Document Type: Article

References (22)

1. Takimoto C.H., Kieffer L.V., and Arbuck S.G. DNA topoisomerase I inhibitors. Cancer Chemother Biol Response Modif 17 (1997) 80-113
2. Houghton P.J., Cheshire P.J., Hallman II J.D., et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36 (1995) 393-403
3. Daw N.C., Santana V.M., Iacono L.C., et al. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. J Clin Oncol 22 (2004) 829-837
4. Santana V.M., Zamboni W.C., Kirstein M.N., et al. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res 9 (2003) 633-640
5. Gerrits C.J., Burris H., Schellens J.H., et al. Oral topotecan given once or twice daily for ten days: A phase I pharmacology study in adult patients with solid tumors. Clin Cancer Res 4 (1998) 1153-1158
6. Chastagner P., Merlin J.L., Marchal C., et al. In vivo potentiation of radiation response by topotecan in human rhabdomyosarcoma xenografted into nude mice. Clin Cancer Res 6 (2000) 3327-3333
7. Chastagner P., Kozin S.V., and Taghian A. Topotecan selectively enhances the radioresponse of human small-cell lung carcinoma and glioblastoma multiforme xenografts in nude mice. In J Radiat Oncol Biol Phys 50 (2001) 777-782
8. Pinel S., Chastagner P., Merlin J.L., et al. Topotecan can compensate for protracted radiation treatment time effects in high grade glioma xenografts. J Neurooncol 76 (2006) 31-38
9. Fisher B., Won M., Macdonald D., et al. Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: Results of Radiation Therapy Oncology Group 9513. Int J Radiat Oncol Biol Phys 53 (2002) 980-986
10. Grabenbauer G.G., Anders K., Fietkau R.J., et al. Prolonged infusional topotecan and accelerated hyperfractionated 3d-conformal radiation in patients with newly diagnosed glioblastoma-a phase I study. J Neurooncol 60 (2002) 269-275
11. Klautke G., Schütze M., Bombor I., et al. Concurrent chemoradiotherapy and adjuvant chemotherapy with Topotecan for patients with glioblastoma multiforme. J Neurooncol 77 (2006) 199-205
12. Gross M.W., Altscher R., Brandtner M., et al. Open-label simultaneous radio-chemotherapy of glioblastoma multiforme with topotecan in adults. Clin Neurol Neurosurg 107 (2005) 207-213
13. Bernier-Chastagner V., Grill J., Doz F., et al. Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: Results of a French Society of Paediatric Oncology Phase II Study. Cancer 104 (2005) 2792-2797
14. MacDonald D.R., Cascino T.L., Schold S.C., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8 (1990) 1277-1280
15. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352 (2005) 987-995
16. Saito R., Krauze M.T., Noble C.O., et al. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro Oncol 8 (2006) 205-214
17. Yamashita Y., Krauze M.T., Kawaguchi T., et al. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicine) in intracranial brain tumor xenografts. Neuro Oncol 9 (2007) 20-28
18. Feun L., and Savaraj N. Topoisomerase I inhibitors for the treatment of brain tumors. Expert Rev Anticancer Ther 8 (2008) 707-716
19. Gupta T., and Dinshaw K. Modified optimal fractionation for poor prognosis malignant gliomas: An elusive search. Acta Oncol 44 (2005) 105-113
20. Prados M.D., Wara W.M., Sneed P.K., et al. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) vs. standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 49 (2001) 71-77
21. Panet-Raymond V., Souhami L., Roberge D., et al. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis. Int J Radiat Oncol Biol Phys 73 (2009) 473-478
22. Tsien C., Moughan J., Michalski J.M., et al. Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: RTOG Trial 98-03. Int J Radiat Oncol Biol Phys 73 (2009) 699-708